Twelve participants were known to have had laboratory-confirmed symptomatic SARS-CoV-2 infection prior to enrolment (all had detectable anti-Spike IgG at baseline); in an additional 19 participants, anti-Spike IgG was detected retrospectively at baseline prior to vaccination (indicative of an asymptomatic infection). This evidence concerns the gene CHMP5 and infection.